Cnat stock zacks
Conatus Pharmaceuticals Inc. (CNAT) Interactive Stock ... Conatus Pharmaceuticals Inc. (CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock Conatus (CNAT) Q3 Earnings: What's in Store for the Stock? Oct 31, 2016 · That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat earnings. That is …
Mar 11, 2020 · SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Wednesday reported a loss of $2.7 million in its fourth quarter. The San Diego-based company said …
Dec 23, 2016 · Want the latest recommendations from Zacks Investment Research?Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. CONATUS PHARMA (CNAT): Free Stock Analysis CNAT Price Target and Analyst Ratings (Conatus ... Nov 04, 2019 · Their average twelve-month price target is $1.50, suggesting that the stock has a possible upside of 391.64%. The high price target for CNAT is $1.50 and the low price target for CNAT is $1.50. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold." CNAT Conatus Pharmaceuticals Inc. — Stock Price and ... Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. CNAT | Conatus Pharmaceuticals Inc. Profile | MarketWatch
Conatus (CNAT) Upgraded to Strong Buy: Here's What You ...
Conatus Pharmaceuticals Inc. - NASDAQ:CNAT - Stock Quote ... View detailed financial information, real-time news, videos, quotes and analysis on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Explore commentary …
Conatus Pharmaceuticals Inc. (CNAT) interactive stock ...
Biotech Stock Roundup: BIIB & CNAT Crash On Study ...
CNAT Stock News and Price / Conatus Pharmaceuticals Inc ...
Nov 06, 2019 · Conatus Pharmaceuticals Inc. company facts, information and stock details by MarketWatch. View cnat business summary and other industry information. CNAT Stock Quote - Conatus Pharmaceuticals Inc. Common ... Mar 27, 2020 · Stock quote for Conatus Pharmaceuticals Inc. Common Stock Common Stock (CNAT) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses ...
May 04, 2018 · Conatus Pharmaceuticals, Inc. is a biotechnology company, which engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. Conatus Pharmaceuticals (NASDAQ:CNAT) - Are Options ... Apr 06, 2018 · Investors in Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) need to pay close attention to the stock based on moves in the options market lately.That is …